Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Biogen Inc. is undergoing a significant strategic transformation, with new product launches now exceeding the decline in its MS portfolio, driven by a focus on de-risked, high-value assets. Key advancements include the recent subcutaneous maintenance approval for Alzheimer's drug LEQEMBI, with a rolling submission for subcutaneous initiation expected mid-next year, and the advancement of its tau ASO (BIIB080) in Phase II. In SMA, Biogen anticipates a quick resubmission for high-dose SPINRAZA following a CMC-related FDA Complete Response Letter and plans a Phase III start for novel ASO salanersen in H1 2026. The company is also aggressively building its lupus franchise with late-stage assets dapi and litifilimab, and has initiated three Phase III trials for felzartamab in rare nephrology, reflecting a broad pipeline strategy to capture significant market opportunities across neurology and immunology.

Analysis

Biogen is demonstrating a significant strategic pivot, evidenced by revenue from its growth products now outpacing the decline of its legacy Multiple Sclerosis (MS) franchise. The Alzheimer's disease portfolio is advancing with the recent U.S. approval for a subcutaneous (subcu) maintenance dose of LEQEMBI, complemented by a rolling submission for a subcu initiation dose, with a regulatory outcome anticipated mid-next year. This development, aimed at providing an at-home autoinjector option, is occurring alongside an exponential increase in the use of blood-based biomarkers, which may accelerate patient diagnosis and expand the addressable market. The Alzheimer's pipeline is further bolstered by BIIB080, an anti-tau ASO with Phase II data expected mid-2026, and the AHEAD 3-45 trial in presymptomatic Alzheimer's. In Spinal Muscular Atrophy (SMA), the company received a Complete Response Letter for high-dose SPINRAZA due to technical CMC issues, not clinical data, and anticipates a rapid resubmission within weeks. The long-term SMA strategy is anchored by salanersen, a next-generation ASO with potential once-yearly dosing, which is slated to enter Phase III in the first half of 2026. Biogen is also aggressively building an immunology franchise, with two late-stage assets in lupus (dapi and litifilimab) and the recently acquired felzartamab, which has already initiated three Phase III trials in rare nephrology indications with first data expected as early as 2027 for AMR.

Key Decisions for Investors

• Investors should recognize that Biogen's financial profile is at an inflection point, with new product growth now offsetting declines in the MS business, warranting a focus on pipeline execution over legacy product performance.
• Monitor the commercial adoption of LEQEMBI, as the potential approval of a subcutaneous initiation dose in mid-2026 represents a major catalyst for expanding market access and simplifying treatment.
• The recent FDA Complete Response Letter for high-dose SPINRAZA appears to be a temporary, solvable manufacturing issue; focus should remain on the swift resubmission and the long-term potential of the next-generation SMA asset, salanersen.
• The immunology pipeline, including late-stage assets in lupus (litifilimab) and rare nephrology (felzartamab), offers significant long-term value and diversification; upcoming Phase III readouts starting in 2026 are key value-unlocking events to watch.